Workflow
Rigel(RIGL)
icon
Search documents
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
Prnewswire· 2024-06-24 20:05
GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif., June 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO® (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by a U.S. Food and Drug Administration (FDA) approved test ...
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
Prnewswire· 2024-06-14 07:05
- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax - New data shows clinically meaningful effect of olutasidenib in patients with mIDH1 AML secondary to MPN and as bridge-to-transplant treatment in patients with R/R mIDH1 AML SOUTH SAN FRANCISCO, Calif., June 14, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today annou ...
Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
Prnewswire· 2024-06-03 12:13
Title: Olutasidenib for Mutated IDH1 Acute Myeloid Leukemia: Final Five-Year Results from the Phase 2 Pivotal Cohort Presenter: Jorge E. Cortes, M.D. - Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax - Data from a subgroup analyses of elderly R/R mIDH1 AML patients treated with olutasidenib shows consistent CR/CRh results - Overview of the Phase 1b trial of R289 in patient ...
Rigel to Present at the Jefferies Global Healthcare Conference
Prnewswire· 2024-05-30 12:05
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads. Rigel Pharmaceuticals, Inc. 650.624.1232 [email protected] Media: David Rosen Argot Partners Phone: 212.600.1902 Email:[email protected] SOUTH SAN FRANCISCO, Calif., May 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodrigue ...
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
prnewswire.com· 2024-05-23 21:00
SOUTH SAN FRANCISCO, Calif., May 23, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced upcoming presentations from their commercial and clinical-stage hematology and oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2024 Hybrid Congress. The ASCO Annual Meeting is being held online and in person in Chicago, Illinois from May 31 to June 4, 2024. The EHA2024 Congress is being held online and in per ...
Rigel(RIGL) - 2024 Q1 - Earnings Call Transcript
2024-05-08 01:46
Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the First Quarter 2024. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. At this time, I would like to turn the call over to our President and Chief Executive Officer, Raul Rodriguez. Raul? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Conference Call May 7, 2024 4: ...
Rigel(RIGL) - 2024 Q1 - Quarterly Results
2024-05-07 20:16
Exhibit 99.1 Rigel Reports First Quarter 2024 Financial Results and Provides Business Update · First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE net product sales of $21.1 million and REZLIDHIA net product sales of $4.9 million · Expanded Rigel's portfolio with acquisition of GAVRETO, a U.S. marketed product for RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer · Appointed Lisa Rojkjaer, M.D. as Chief Medical Officer · Conference ca ...
Rigel(RIGL) - 2024 Q1 - Quarterly Report
2024-05-07 20:05
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (St ...
Rigel(RIGL) - 2023 Q4 - Earnings Call Transcript
2024-03-06 03:20
And lastly, R289, our IRAK1 and 4 inhibitor, is continuing to enroll its Phase 1b trial. We hope that this program demonstrates the potential of R289 to provide patients who have failed other agents with a much needed treatment option. We expect to have preliminary data from the first part of this trial late this year. With that, let me turn to Slide 25 to review the strategic efforts with MD Anderson. There are four patient populations that we and MD Anderson are particularly excited about for olutasidenib ...
Rigel(RIGL) - 2023 Q4 - Annual Report
2024-03-05 21:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-29889 RIGEL PHARMACEUTICALS, INC. Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of ...